EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

IL-6 receptor blockade impedes proinflammatory atypical Treg subset associated with immune checkpoint inhibitor–induced inflammatory arthritis

Yifei Ma, Nianqi Liu, Yan Li, Denghan Zhang, Shaohui He, Jun Lv, Yongluo Jiang, Guangmin Jian, Jingyao Zhang, Pengfei Zhu, Yue Ma, Jiacai Lin und 25 weitere

Journal of Clinical Investigation · 01.07.2026 · 136 (13)

DOI: 10.1172/jci200135 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 12.05.2026. Verfasst von Yifei Ma und 36 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, T-Lymphocytes, Regulatory, Receptors, Interleukin-6, Arthritis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Foundation of China General Fund Project, National Natural Science Foundation of China Youth Science Fund Project, the Innovation of Science and Technology, Fujian Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Immune checkpoint inhibitor–induced inflammatory arthritis (ICI-IA) significantly impairs cancer therapy and patient quality of life, yet its pathogenic mechanisms remain unclear. METHODS Through integrated single-cell multi-omics analysis of paired peripheral blood, synovial fluid, and tumor samples from longitudinal ICI-IA cohorts and matched controls, we identified a unique regulatory T-cell (Treg) population coexpressing CD137 and IL-6R (AtpTreg). RESULTS These cells exhibited reduced immunosuppressive capacity while aberrantly producing high levels of IL-17 and promoting proinflammatory responses of synoviocytes. AtpTreg exhibits shared clonotypes and phenotypes across tissue compartments. Notably, AtpTreg frequency correlates with increased arthritis severity yet paradoxically associates with improved overall survival. Anti-IL6R therapy reduced AtpTreg levels, corresponding with improved arthritis outcomes and quality of life, without compromising anti-tumor immunity. CONCLUSION Our findings define a pathogenic Treg subset in ICI-IA and validate IL-6R blockade as a mechanism-based therapeutic strategy, bridging mechanistic discovery to clinical translation. TRIAL REGISTRATION NCT07357636. FUNDING The National Natural Science Foundation of China General Fund Project; National Natural Science Foundation of China Youth Science Fund Project; Regional joint key support project of National Natural Science Foundation of China; Natural Science Foundation of Fujian Province; Joint Funds for the Innovation of Science and Technology, Fujian Province.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsT-Lymphocytes, RegulatoryReceptors, Interleukin-6ArthritisHumansFemaleMale

Stichwörter der Autor:innen

Cancer immunotherapyImmunologyOncology

Substanzen

Immune Checkpoint InhibitorsReceptors, Interleukin-6IL6R protein, human

Autor:innen und Institutionen

  • Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
  • Institute of Abdominal Surgery, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
  • Fujian Provincial Key Laboratory of Precision Medicine for Cancer, the First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
  • Department of Hepatobiliary and Pancreatic Surgery, National Regional Medical Center Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
  • Faculty of Psychology, Institute of Educational Science, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Pathology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen Univ…

Förderung

  • the National Natural Science Foundation of China General Fund Project
  • National Natural Science Foundation of China Youth Science Fund Project
  • the Innovation of Science and Technology, Fujian Province
  • Regional joint key support project of National Natural Science Foundation of China

Zitieren

APA

Ma, Y., Liu, N., Li, Y., Zhang, D., He, S., Lv, J., Jiang, Y., Jian, G., Zhang, J., Zhu, P., Ma, Y., Lin, J., Li, J., Wu, T., Xu, Y., Lyu, X., Wang, Y., Li, Y., Niu, Y. S., …, & Zhang, A. (2026). IL-6 receptor blockade impedes proinflammatory atypical Treg subset associated with immune checkpoint inhibitor–induced inflammatory arthritis. Journal of Clinical Investigation, 136(13). https://doi.org/10.1172/jci200135

Vancouver

Ma Y, Liu N, Li Y, Zhang D, He S, Lv J, et al. IL-6 receptor blockade impedes proinflammatory atypical Treg subset associated with immune checkpoint inhibitor–induced inflammatory arthritis. Journal of Clinical Investigation. 2026;136(13). doi:10.1172/jci200135

BibTeX
@article{Ma2026,
  author = {Ma, Yifei and Liu, Nianqi and Li, Yan and Zhang, Denghan and He, Shaohui and Lv, Jun and Jiang, Yongluo and Jian, Guangmin and Zhang, Jingyao and Zhu, Pengfei and Ma, Yue and Lin, Jiacai and Li, Jin and Wu, Tong and Xu, Yiwei and Lyu, Xiajie and Wang, Youlong and Li, Yiming and Niu, Yu Si and Guo, Zhenyun and Lin, Churong and Fang, Ningnan and Jiang, Wei and Wang, Lihong and Yuan, Mengqin and Wang, Shenyue and Huang, Shulin and Huang, Qi and Li, Jinjian and Lu, Jun and Chen, Bocen and Zhong, Guanqing and Liu, Haizhou and Ding, Fadian and Weng, Shangeng and Li, Rui and Zhang, Ao},
  title = {IL-6 receptor blockade impedes proinflammatory atypical Treg subset associated with immune checkpoint inhibitor–induced inflammatory arthritis},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  volume = {136},
  number = {13},
  doi = {10.1172/jci200135}
}
Kostenlos starten →